Yussim 2000.

Methods	Study design: parallel RCT Study duration: not reported Study follow‐up: 2 years
Participants	Country: Israel Setting: single centre Inclusion criteria: low and high risk 1st or retransplant kidney transplant recipients Number: treatment group (19); control group (19) Mean age ± SD (years): not reported Sex (M/F): not reported Exclusion criteria: not reported
Interventions	Treatment group rATG (Fresenius): single dose of 9 mg/kg given as IV infusion in 500 mL saline prior to revascularistion MP: 500 mg Control group No ATG Immunosuppression (both groups) PRED: as per protocol, started post‐op; dosage not reported AZA: as per protocol, started post‐op; dosage not reported CSA: as per protocol, started post‐op; dosage not reported
Outcomes	Death Graft loss Acute rejection DGF Infection
Notes	Graft function reported but timing not specified and no SD or SE given, cannot be meta‐analysis Funding source: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Unlikely to influence outcomes
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Unlikely to influence outcomes
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patient outcome data reported
Selective reporting (reporting bias)	High risk	All expected outcomes reported however SD/SE not reported for graft function
Other bias	Unclear risk	Insufficient information to permit judgement

ALG ‐ antilymphocyte globulin; ANC ‐ absolute neutrophil count; ATG ‐ antithymocyte globulin; ATGAM ‐ horse ATG; ATN ‐ acute tubular necrosis; AZA ‐ azathioprine; BKV ‐ BK virus; CAN ‐ chronic allograft nephropathy; CMV ‐ cytomegalovirus; CNI ‐ calcineurin inhibitor; CSA ‐ cyclosporin A; DD ‐ deceased donor; DGF ‐ delayed graft function; DEX ‐ dexamethasone; EBV ‐ Epstein–Barr virus; eGFR ‐ estimated glomerular filtration rate; ESKD ‐ end‐stage kidney disease; GI ‐ gastrointestinal; hATG ‐ horse ATG; Hep ‐ hepatitis; HIV ‐ human immunodeficiency virus; HLA ‐ human leukocyte antigen; IL‐2RA ‐ interleukin 2 receptor antagonist; IV ‐ intravenous; LD ‐ living donor; mALG ‐ Minnesota ALG; M/F ‐ male/female; MMF ‐ mycophenolate mofetil; MP ‐ methylprednisolone; NODAT ‐ new‐onset diabetes after transplantation; post‐op ‐ post‐operative; PRA ‐ panel reactive antibodies; PRED ‐ prednisone; PTLD ‐ post‐transplant lymphoproliferative disease; rATG ‐ rabbit ATG; RBC ‐ red blood cell; RCT‐ randomised controlled trial; SCr ‐ serum creatinine; SD ‐ standard deviation; SE ‐ standard error; SEM ‐ standard error of the mean; WCC ‐ white cell count